You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirementsSBC: PASCALL Systems, Incorporated Topic: NIDA
PROJECT SUMMARY In light of the opioid crises, minimizing postoperative pain and postoperative opioid requirements to reduce chronic opioid dependency among surgical patients have become major concerns for surgeons and anesthesiologists. Effective intraoperative nociception control can mitigate these concerns. Unfortunately, existing nociceptive monitoring tools use indicators that are inherently ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: TENDEL THERAPIES INC Topic: NIAID
This project will establish proof-of-concept for CCR5 immunotoxins as HIV reservoir-depletion agents for use in cure strategies. HIV cure and remission strategies require elimination or reduction of the HIV reservoir. Approaches to reservoir reduction pursued by other groups include gene editing, i.e., direct removal of integrated provirus; latency reversal and an accompanying “kill” strategy; ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: GENERAL NANOTHERAPEUTICS LLC Topic: NIAID
ABSTRACT Current pharmaceutical agents that are used for the treatment of immune-mediated inflammatory conditions including autoimmune diseases generally do not lead to remission and frequently carry toxic side effects. Here we propose a strategy that can harness the capacity of the immune system to induce immunoregulatory response that can suppress immune hyperactivity and chronic inflammation in ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: FRAMESHIFT LABS INC Topic: 172
Summary/Abstract Genomic sequencing is rapidly becoming a standard tool in diagnosing complex diagnostic cases, especially in critically ill newborns, and patients suffering from rare diseases. Current programs focused on addressing these cases utilise a team-based approach to identify, interpret and evaluate a patient’s genetic variants. These diverse teams include bioinformaticians, medical ge ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercializationSBC: FELIX BIOTECHNOLOGY INC Topic: NIAID
ABSTRACT Antibiotic-resistant infections are a major public health threat in the U.S. and globally, with Pseudomonas aeruginosa (Pa) being one of the top pathogens of concern. Phage therapy is a promising approach to treat these infections, with benefits of species-targeted activity that spares the host microbiome, an ability to penetrate biofilms and kill metabolically-inactive persister cells, a ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBCSBC: DNATWO, Inc. Topic: NCI
DNATWO, Inc. was founded out of Caltech to develop small molecule drugs targeting a new cancer target, DNA2, to treat triple-negative breast cancer (TNBC). We have spent decades unraveling the role of the DNA2 ATP-motor driven nuclease activity in relieving replication stress at the replication fork and carrying out repair at forks collapsed to double strand breaks (DSBs). Our scientific premise i ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Medical Predictive Science Corporation Topic: NICHD
Project Summary/Abstract: Clinical Decision Support System to Optimize Neonatal Nutrition and Growth Nutrition, defined as energy, macronutrients (protein, fat, and carbohydrates), and micronutrients (e.g., electrolytes), is a critical feature of care for preterm infants in the neonatal intensive unit (NICU). Inadequate nutrition is associated with growth and neurodevelopmental impairment, and inc ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorderSBC: ELEVEN THERAPEUTICS CORP Topic: NIDA
Abstract There is a significant need for new treatments for opioid use disorder (OUD) to manage patients abusing heroin, fentanyl, oxycodone and related drugs. Buprenorphine and methadone are both effective medications for OUD but are agonists with potential for abuse and diversion, and with methadone the risk of respiratory depression and overdose death. Moreover, these compounds are not effectiv ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOSYNESIS, INC. Topic: NIAID
Project Summary/Abstract Members of the Candida genus of fungi form part of the normal human microbiota but are also opportunistic pathogens capable of causing serious mucosal and systemic infections. Candida cells grow and divide in suspension (planktonic) cultures, but they also form resilient and drug resistant biofilms – organized, tightly- packed communities of cells that attach to surfaces ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NIAID
PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from pulmonary injury from viral infections, as demonstrated by the severe impact of COVID-19, which is a global pandemic that, at the time of writing, is estimated have impacted approximately 50 million people in the United States, leading to morbidity, substantial hospital and intensive care ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health